{"address1": "12770 High Bluff Drive", "address2": "Suite 150", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "(619) 949-3681", "website": "https://www.gyretx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.", "fullTimeEmployees": 579, "companyOfficers": [{"maxAge": 1, "name": "Mr. Songjiang  Ma", "age": 68, "title": "President & Chairman", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Han  Ying Ph.D.", "age": 58, "title": "CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 10500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruoyu  Chen", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 121352, "exercisedValue": 0, "unexercisedValue": 15073756}, {"maxAge": 1, "name": "Mr. Weiguo  Ye", "age": 46, "title": "Chief Operating Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 274617, "exercisedValue": 0, "unexercisedValue": 41527968}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 7.72, "open": 8.22, "dayLow": 6.17, "dayHigh": 8.22, "regularMarketPreviousClose": 7.72, "regularMarketOpen": 8.22, "regularMarketDayLow": 6.17, "regularMarketDayHigh": 8.22, "payoutRatio": 0.0, "trailingPE": 128.2, "forwardPE": 13.934782, "volume": 404891, "regularMarketVolume": 404891, "averageVolume": 132785, "averageVolume10days": 304320, "averageDailyVolume10Day": 304320, "bid": 6.38, "ask": 6.53, "bidSize": 2, "askSize": 1, "marketCap": 600055488, "fiftyTwoWeekLow": 6.17, "fiftyTwoWeekHigh": 19.0, "priceToSalesTrailing12Months": 5.673908, "fiftyDayAverage": 10.9828, "twoHundredDayAverage": 12.13175, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 610065728, "profitMargins": 0.11427, "floatShares": 23939510, "sharesOutstanding": 93612400, "sharesShort": 1526887, "sharesShortPriorMonth": 1254517, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0163, "heldPercentInsiders": 0.80841005, "heldPercentInstitutions": 0.02122, "shortRatio": 17.59, "shortPercentOfFloat": 0.10520001, "impliedSharesOutstanding": 93612400, "bookValue": 0.734, "priceToBook": 8.732969, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": 12085000, "trailingEps": 0.05, "forwardEps": 0.46, "lastSplitFactor": "1:15", "lastSplitDate": 1698710400, "enterpriseToRevenue": 5.769, "enterpriseToEbitda": 34.241, "52WeekChange": -0.62645686, "SandP52WeekChange": 0.08089435, "lastDividendValue": 3.6, "lastDividendDate": 1673568000, "quoteType": "EQUITY", "currentPrice": 6.41, "targetHighPrice": 20.0, "targetLowPrice": 20.0, "targetMeanPrice": 20.0, "targetMedianPrice": 20.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 26671000, "totalCashPerShare": 0.285, "ebitda": 17817000, "totalDebt": 1598000, "quickRatio": 2.636, "currentRatio": 3.32, "totalRevenue": 105757000, "debtToEquity": 1.624, "revenuePerShare": 1.243, "returnOnAssets": 0.083850004, "returnOnEquity": 0.20238, "grossProfits": 101873000, "freeCashflow": -6002875, "operatingCashflow": -3641000, "revenueGrowth": 0.027, "grossMargins": 0.96327, "ebitdaMargins": 0.16847, "operatingMargins": 0.02379, "financialCurrency": "USD", "symbol": "GYRE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1144848600000, "shortName": "Gyre Therapeutics, Inc.", "longName": "Gyre Therapeutics, Inc.", "corporateActions": [], "regularMarketTime": 1743537601, "exchange": "NCM", "messageBoardId": "finmb_100542295", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -16.968912, "regularMarketPrice": 6.41, "cryptoTradeable": false, "marketState": "PRE", "regularMarketChange": -1.31, "regularMarketDayRange": "6.17 - 8.22", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 132785, "fiftyTwoWeekLowChange": 0.23999977, "fiftyTwoWeekLowChangePercent": 0.038897857, "fiftyTwoWeekRange": "6.17 - 19.0", "fiftyTwoWeekHighChange": -12.59, "fiftyTwoWeekHighChangePercent": -0.6626316, "fiftyTwoWeekChangePercent": -62.645687, "dividendDate": 1673481600, "earningsTimestamp": 1739885400, "earningsTimestampStart": 1746615540, "earningsTimestampEnd": 1747051200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 0.05, "epsForward": 0.46, "fiftyDayAverageChange": -4.5727997, "fiftyDayAverageChangePercent": -0.4163601, "twoHundredDayAverageChange": -5.7217503, "twoHundredDayAverageChangePercent": -0.47163436, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.0 - Strong Buy", "displayName": "Gyre Therapeutics", "trailingPegRatio": null}